Sr versus Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma

Nuclear Medicine Communications

Volumn 28, Issue 4, 2007, Pages 245-250

  Bączyk, Maciej ^a   Czepczyński, Rafał ^a   Milecki, Piotr ^a   Pisarek, Marlena ^b   Oleksa, Robert ^b   Sowiński, Jerzy ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Great Poland Cancer Centre   (Poland)

Author keywords

Bone metastases; Samarium 153; Strontium 89

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; LEXIDRONAM SAMARIUM SM 153; MEDRONATE TECHNETIUM TC 99M; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; STRONTIUM 89;

ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER PAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPERCALCEMIA; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PANCYTOPENIA; PROSTATE CARCINOMA; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; VISUAL ANALOG SCALE;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; STRONTIUM RADIOISOTOPES; TREATMENT OUTCOME;

EID: 34247636849     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32805b72a0     Document Type: Article

References (19)

1. Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res 1995; 312:64-75.
2. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol 1991; 9:509-524.
3. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001; 28 (4 suppl 11):28-34.
4. Silberstein EB. Advances in our understanding of the treatment of painful metastases. J Nucl Med 2000; 41:655-657.
5. Lass P. Radionuclide treatment of bone metastases - current concepts and trends. Nucl Med Rev Cent East Eur 2001; 4:1-3.
6. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systemic review. Lancet Oncol 2005; 6:392-400.
7. Ron IG, Stav O, Vishne T, Evan-Sapir E, Soyfer V, Agai R, et al. The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases. Am J Clin Oncol 2004; 27:500-504.
8. Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von Der Maase H, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer. Genitourinary Group. Eur Urol 2003; 44:519-526.
9. Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 2005; 35:152-158.
10. McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 2000; 10:103-114.
11. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46 (suppl 1):38S-47S.
12. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis - a systemic review. Radiother Oncol 2005; 75:258-270.
13. Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA, Martin NL, et al. Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989; 9:271-278.
14. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28:788-798.
15. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam; a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574-1581.
16. 153Sm in bone. Appl Radiat Isot 2001; 54:269-274.
17. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005; 23:7904-7910.
18. Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000; 27:1487-1493.
19. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36:1902-1909.